Natural or synthetic retroelement sequence enabling nucleotide sequence insertion into a eukaryotic cell
CA 2226301 C · Owner: Institut Pasteur · Inventors: Nicolas, Jean-Francois; Choulika, Andre
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Retroviral vectors contain cis-acting viral elements for the expression encapsidation, reverse transcription and integration of the retroviral genome nucleic acid sequence. However said elements are not useful in the integrated provirus and may cause many problems. A retroviral vector is provided for eliminating most of the viral elements. Said vector uses inter alia, the bacteriophage P1 Cre-lox recombination system. The 32-nucleotide loxP site is inserted into 3'LTR sequence U3 with the gene to be inserted into the cell. After loxP duplication using the LTR the LTRs may be recombined by enzyme Cre. The structure of the resulting provirus in the host genome corresponds to a single LTR …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 25, 1996 and granted April 19, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended July 25, 2016.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 25, 2018.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.